Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Altimmune Inc(ALT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ALT
09/24/2026: ALT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Altimmune Inc is a clinical-stage biotechnology company focused on developing peptide-based treatments for obesity and MASH, with its primary asset being the drug candidate pemvidutide. The company's main strength lies in its specialized R&D pipeline that targets the GLP-1 and glucagon pathways. Its primary investment story hinges on the success of its clinical trials and the potential for a lucrative licensing or acquisition deal. However, the company faces high risks, including lack of commercial revenue, significant cash burn, and intense competition from major pharmaceutical players. It is best suited for growth-oriented investors with a high risk tolerance who are willing to monitor ongoing clinical trial data developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company represents a speculative growth opportunity based on clinical pipeline outcomes rather than existing growth metrics. |
| Momentum investor | Strong fit while signal remains positive | The stock often experiences significant price swings based on clinical news, which can suit momentum-based trading strategies. |
| Value investor | Weak fit | The lack of earnings and assets makes it unsuitable for traditional value-based investment strategies. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses entirely on R&D investment. |
| Low-risk investor | Weak fit | The high clinical, regulatory, and financial risks are inappropriate for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is highly sensitive to news, trial data, and market sentiment. |
| Valuation risk | High | Valuation is based on speculative future pipeline success rather than fundamental earnings. |
| Competition risk (metabolic drugs) | High | The market is dominated by well-funded incumbents with large, approved drug portfolios. |
| Business quality | Medium | The business relies on a thin, R&D-centric pipeline with no current commercial revenue. |
| Dividend income | Low / none | There is no income generation for investors. |
| Execution risk | High | Failure at any clinical trial stage would materially impair the company's value. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -20.99% | Avg. Invested days 26 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/24/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 620.51M USD | Price to earnings Ratio - | 1Y Target Price 17.11 |
Price to earnings Ratio - | 1Y Target Price 17.11 | ||
Volume (30-day avg) 4.1M shares | Beta 0.18 | 52 Weeks Range 2.56 - 6.44 | Updated Date 09/24/2026 |
52 Weeks Range 2.56 - 6.44 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.71 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Biopharmaceutical R&D | Clinical trial development of peptide therapeutics. | The company does not currently sell products; it creates value by developing potential new drugs for future licensing or sale. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 8.18 | Enterprise Value 373.04M | Price to Sales(TTM) 20016.5 |
Enterprise Value 373.04M | Price to Sales(TTM) 20016.5 | ||
Enterprise Value to Revenue 12033.69 | Enterprise Value to EBITDA 11.93 | Shares Outstanding 194.52M | Shares Floating 164.38M |
Shares Outstanding 194.52M | Shares Floating 164.38M | ||
Percent Insiders 0.42 | Percent Institutions 77.85 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Altimmune Inc
Exchange NASDAQ | Headquarters Gaithersburg, MD, United States | ||
IPO Launch date 2005-10-06 | Chairman, CEO & President Mr. Jerome Benedict Durso | ||
Sector Healthcare | Industry Biotechnology | Full time employees 57 | Website https://altimmune.com |
Full time employees 57 | Website https://altimmune.com | ||
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.